Avadel Pharmaceuticals plc's (AVDL) pivotal phase III trial evaluating FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy has met its three co-primary efficacy endpoints at all three doses.
from RTT - Biotech https://ift.tt/3cXxjhf
via IFTTT
No comments:
Post a Comment